Log In
BCIQ
Print this Print this
 

E2609

  Manage Alerts
Collapse Summary General Information
Company Eisai Co. Ltd.
DescriptionBeta-site APP-cleaving enzyme (BACE) inhibitor
Molecular Target Beta-site APP-cleaving enzyme 1 (BACE1)
Mechanism of ActionBeta-site APP-cleaving enzyme 1 (BACE1) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD); Treat early Alzheimer's disease (AD)
Regulatory Designation
PartnerBiogen Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$100.0M

0


 Deals Details
Get a free BioCentury trial today